HOOKIPA Pharma Inc. (HOOK)
| Symbol | HOOK |
|---|---|
| Price | $ 1.76 |
| Beta | 1.005 |
| Volume Avg. | 0.24M |
| Market Cap | 0.053B |
| Shares () | - |
| 52 Week Range | 1.75-20.0 |
| 1y Target Est | - |
| DCF Unlevered | HOOK DCF -> | |
|---|---|---|
| DCF Levered | HOOK LDCF -> | |
| ROE | -50.48% | Strong Sell |
| ROA | -47.06% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 31.54% | Neutral |
| P/E | - | |
| P/B | 0.54 | Buy |
Latest HOOK news
About
Download (Excel)HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.